Mitchell Gold: Yeah, our trials both are doing things in a two four week dose regimen and as at all doses, for both doses being tested. As far as we are aware, RemeGen is 160 milligrams of Sub-Q weekly and it appears to be the doses for all their pivotal trials. So, when the person where Q4 versus Q1 week. As you know, we start to talk about best-in-class potential for POVI where the key things that differentiate us is, one that we were potent, two that we have a much more convenient dosing schedule and the fact that we cover both cytokines more completely than either of the wild-type TACI €“ in three broad development plan going forward.
Mark Breidenbach: Got it. Thanks for taking my questions.
Mitchell Gold: Thank you.
Operator: And we’ll take our last question from the line of with Joe Pantginis with H.C. Wainwright. Please go ahead.
Joe Pantginis : Hey everybody. Good afternoon. Thanks taking the question. Wanted to get a little more color if you can regarding the end-of-year initial data from both RUBY- 3 and RUBY-4. Is this going to be essentially, early response type of data for each type of indication or can we get more than that initially with regard to say any translational or PD data?
Mitchell Gold: Yeah, we’ll be focusing quite a bit on both traditional endpoints, as well as biomarker-related data. So, PD endpoints, including immunoglobulintarget, cytokine targets, as well as biomarkers or things like a Gd-IgA1 in IG nephropathy as each of these indications has their respective antibody that we will be looking at. So we’ll be looking all of that and look forward to be able to report that early this year.
Joe Pantginis : That’s great. And do you think you could just remind, I mean, since it’s a basket concept, how many per indication you’re looking for and how many you think that might deliver for the initial data?
Mitchell Gold: It’s a basket trial. We’ll see harmonization that I can say that we’re getting interest. The recent RUBY-3 so far we are getting interest in across all the different subtypes, lupus nephritis and primary membranous nephropathy. Exactly how that mix is going to shake out surely to say right now, but early on we’re pretty pleased with the mix of interest that’s coming into the trial.
Joe Pantginis : Sure, got it. Thanks a lot.
Mitchell Gold: Thanks.
Operator: There are no for the questions, Dr. Gold. I’ll turn the call back over to you.
Mitchell Gold: Thank you operator. Thank you all for taking part in today’s call. We look forward to seeing many of you in upcoming investor and medical meetings and providing updates in the months ahead. Thank you and have a great afternoon.
Operator: Thank you ladies and gentlemen. This concludes our call today. You may now disconnect.
